Paul Blundell is the President of Organix, where he has served for over 32 years. Paul specializes in medicinal chemistry and drug discovery, managing preclinical research for both small and large molecules. His technical expertise spans the tropane, lipid, and opioid areas, with a particular interest in imaging agents and polymer synthesis and characterization. Paul’s Ph.D. in Organic Chemistry was conducted under the direct supervision of Nobel laureate Sir Derek Barton. Paul’s research has resulted in 12 patents and over 24 publications.